VST BIO Corporation Closes Series A to Advance Stroke Antibody VB-001 Into the Clinic
VST BIO Corporation, a San Diego-headquartered biotechnology company developing therapeutics for acute ischemic stroke, has closed a Series A financing round. Coefficient Giving, a philanthropic funder focused on global health and science R&D, led the round. Total investment in the company since its founding in 2020 now stands at USD 45 million, the company said. Proceeds will be used to advance lead candidate VB-001 into first-in-human studies in 2026, expand the company's platform, and build development capabilities.
The round was led by Coefficient Giving and its funding partners. No other investors were named in the company's announcement. Coefficient Giving, which has directed more than USD 4 billion in grants since 2014, works with philanthropists to deploy capital in areas it considers high-impact, including global health and scientific research. The USD 45 million figure represents cumulative investment since VST BIO's inception rather than the Series A tranche alone; the company did not disclose the specific size of the Series A.
VB-001 is a monoclonal antibody described as first-in-class, targeting vascular inflammation and edema. The company's preclinical data indicate efficacy in models of acute ischemic stroke, sepsis, and cytokine release syndrome. Stroke remains the primary indication. VST BIO is currently at the preclinical stage and has no approved products. The planned first-in-human study for VB-001 would represent the company's entry into clinical development. No trial registration or design details have been disclosed.
The scientific rationale centers on the role of endothelial barrier dysfunction and vascular inflammation in driving secondary injury after ischemic stroke. Current standard-of-care treatments, including thrombolysis and mechanical thrombectomy, address blood flow restoration but do not target the inflammatory cascade that leads to blood-brain barrier breakdown, cerebral edema, and further tissue damage in the hours and days following the initial event. VST BIO's approach with VB-001 aims to intervene at this vascular inflammatory level.